Silence Therapeutics’ Divesiran Shows Promise in PV Study
Company Announcements

Silence Therapeutics’ Divesiran Shows Promise in PV Study

Silence Therapeutics (SLN) has released an update.

Silence Therapeutics has reported promising outcomes from its Phase 1 SANRECO study of divesiran in polycythemia vera patients, showing elimination of phlebotomy requirements in well-controlled individuals and a good safety profile. The data supports the progression of divesiran into Phase 2 trials. With its potential as the first siRNA therapy for this condition, divesiran demonstrates sustained reduction in hematocrit and favorable effects on iron metabolism indicators.

For further insights into SLN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlySilence Therapeutics files automatic ordinary shares offering
TheFlyAstraZeneca deal has positive read for Silence Therapeutics, says Morgan Stanley
TheFlyAstraZeneca, CSPC deal shows Lp(a) space remains hot, says BMO Capital
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App